Foghorn Therapeutics Appoints Michael LaCascia as Chief Legal Officer
November 12, 2020 09:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...
Foghorn Therapeutics Announces Pricing of Initial Public Offering
October 22, 2020 21:24 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...